



9TH ANNUAL
**ANIMAL HEALTH, NUTRITION
 & TECHNOLOGY INNOVATION
 ASIA**

October 7-8 • Tokyo
 @AHIInnovation #AHTNI

INNOVATION SHOWCASE FINALISTS 2024

Animal Health, Nutrition and Technology Innovation Asia is the premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.



We are proud to announce the **8 finalist companies** selected to present at the 2024 Innovation Showcase.



INNOVATION SHOWCASE FINALISTS



SERIES A

AgBoost is the leading genetics testing and herd management platform, where livestock producers can own, control and understand their herd genetic and performance data. AgBoost tools allows livestock producers to make data driven breeding and marketing decisions.

AgBoost is the 23&me of livestock industry and the only platform technology in the world that allows cattle producers, with one click of a button order DNA test online and visually analyse/ interact with genetic data. From using genomic data to make breeding decisions, to marketing animals online on AgBoost Marketplace, our proprietary data visualization/analytics tools can also be leveraged in both companion animals and human health space. AgBoost has utility patent in genomic technology in U.K and China and patent pending in the U.S, Canada, Brazil and Mexico. With almost 500,000 animals in their data base our current customers ranges from the small, midsize to large ranches.



NOT SPECIFIED

Amorphical is a biotechnology company dedicated to the development of novel veterinary and human drugs. Using its nano-amorphous platform technology, Amorphical focuses on drug for metabolic and inflammatory bone diseases.

In the field of veterinary medicine, Amorphical Animal Health is working on the development of a novel oral drug for osteoarthritis (OA) in dogs, to controlling the pain, inflammation and the joint structural changes associated with the disease.

Amorphical has successfully completed a pilot, double blinded, controlled clinical study in dogs with OA. Following the registration of ACC as a drug for OA in dogs (<https://doi.org/10.3389/fvets.2024.1381941>). A follow up registration for its use in cats and horses is planned.



NOT SPECIFIED

DelstAsia S/B is a solution provider for Grain & Feed quality. Their founder, Stephen Goh has spent upwards of 15 years unravelling the complexity of thermal feed processing, specifically in the areas that affect pellet quality and nutrient integrity of the processed pellet feed. They have since introduced a patented approach in moisture diffusion for processing feed, naming it Hydro-Thermal Feed Processing. This is an exciting new direction to improve proper processing of starch & protein and the overall processed feed quality - a total solution for improved pellet integrity and feeding value of processed feed.

They are the first to delve into a hidden area that greatly affects feed nutrition. This is a huge contribution as their hydro thermal feed processing deals with proper processing of starch & protein - can help harvest back roughly 5% of energy and feeding value. There is a lot of lost caused as a result of the industry feed production engineering setup which has not addressed the need for moisture diffusion for proper chemistry changes to starch and protein.



INNOVATION SHOWCASE FINALISTS



PRE-SEED

MACSO is a Technology Platform company focused on bringing intelligence to sensors for a variety of environmental monitoring, early risk detection and prevention of major catastrophes. Their AI-enabled audio sensors for Swine leverage our proprietary data and AI models for early disease detection, prevention of disease spread and reduction of death rate caused by respiratory illnesses. Their US pilot farm has shown an incredible death rate reduction from an average of 4.8% per month to 1.5% after using the MACSO solution.

They are experts at deploying complex artificial intelligence models on the edge. This way, they reduce the requirement for internet connectivity significantly, optimising the solution for rural connectivity. Furthermore, their devices are 100% private and secure and no audio data will ever leave the farm. This makes their solution secure, and trustworthy for the farmers.



SERIES A

Supine Therapeutics Co., Ltd. is a bio venture company founded by Professor Jeong Beom Kim established in 2017 with the goal of developing a treatment for incurable spinal cord injuries.

Their main pipeline, SGS101/SGD101, is an implantable hydrogel composed of FDA-approved biomaterials (drug repositioning). It is expected to be the First-in-class treatment for spinal cord injury providing a fundamental treatment for spinal cord injury, and considered as best-in-class therapeutics since it shows significant efficacy after treatment.

In order to commercialize this technology as a veterinary medicine (SGD101) for treating dogs with Intervertebral disc disease (IVDD), they confirmed the efficacy in dog patients with spinal cord damage caused by disc herniation. Product development has been completed, and toxicity tests conducted by GLP facility have been confirmed to be non-toxic.

Their IVDD treatment for animals is categorized as an animal medical device in South Korea. SuPine Therapeutics was approved as an "Animal Medical Device Manufacturing Business" in December 2023, and also received market approval as animal medical device addressing, anti-adhesion barrier (Hydrogel for treating spinal cord injury/disc disease in April 2024.



INNOVATION SHOWCASE FINALISTS



Vaccine Solutions for the 21st Century

SEED

The Vaccine Group (TVG) are a vaccine biotech start up established in 2017 as spin out from the University of Plymouth, England. Focused on a tuneable viral vector technology platform for gene delivery with immunological or biological function across domesticated and wildlife species. Through grant, equity and commercial partnership funding they have established a portfolio of candidate vaccines across a number of domesticated species. We are in the process of looking at the delivery of biotherapeutics using the enhanced version of our viral vector platform technology.

Their vector accommodates large genetic insertions coding for several proteins, which can be from the same or different pathogens. This offers the option for a single construct combination vaccine. There is no interfering vector immunity induced and therefore the vector can be used repeatedly. Production is simple using an existing commercially available suspension cell line. The inherent self-adjuvanting nature of the herpesvirus vector provides strong baseline T cell immunity, which can be modified to drive serological responses also. High titre growth of the candidate vaccines compared to immunising dose drives very low production costs. The vector can be used safely and effectively across the domesticated species.



SEED

Vetanic Inc is a start-up biotech venture in Japan developing regenerative medicine for companion animals with animal iPS (induced-pluripotent stem) cells. Their breakthrough proprietary technology enables them to establish iPSC of dogs, cats and horses, that are known to be a resistant to induce pluripotency. In addition, their animal iPSC is induced without using virus vector, thus regarded as clinical grade cells. Currently, Vetanic is developing canine iMSC, which is the mesenchymal stem cells induced from iPS cells, similar to adipose-derived MSC.

iMSC (iPSC-derived MSC) is a donor free, high uniformity and low manufacturing cost. Instead of living organs such as fat or bone marrow, they use Master Cell Bank to obtain iMSC, hence donor free is achievable. Such MCB is highly homogeneous, therefore, quality of iMSC also results in high uniformity. This property is particularly important to increase predictability of safety and efficacy. Starting manufacturing from MCB, process can be simplified, thus cost can be reduced. Moreover, iMSC is also differentiated into other cells like cartilage, just like a pluripotency of iPSC, broader therapeutic application is possible to develop.



SERIES C

ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline.

Their vaccine technology enables them to design and produce vaccines at low COG, easily adaptable, thermally stable and triggering both arms of the immune system. Antiviral drugs to block viral replication when vaccines are not available or too slow (emergencies/outbreaks/etc).



CONNECTIONS

Our Swapcard platform allows you to preschedule meetings with these exciting start-ups!

Animal Health, Nutrition and Technology Innovation Asia is committed to bringing innovative and inspiring emerging companies together with partners looking to acquire and invest.

To ensure all our attendees make the most valuable connections possible at the Summit, the SWAPCARD platform allows you to create a bespoke meeting schedule, ensuring you connect with the industry stakeholders that are most important in building your business.

SWAPCARD gives you access to the entire attendee list and allows you to message AND

SCHEDULED MEETINGS

Who You Will Meet

- + Start-Ups & Early Stage Biotech Companies
- + Business Development Teams from International Pharmaceutical Companies
- + Leadership from Multinational Corporations
- + Mid to late-stage Health and Nutrition Companies
- + Global Distribution Leaders
- + Venture Capital and Private Equity Investors
- + Market Intelligence and Consultancy Providers
- + Universities and National Regulatory Bodies
- + Contract Research & Contract Manufacturing

Find out more:
VIEW THE AGENDA

Join the Finalists:
REGISTER TODAY



VENUE & PRICING

Sheraton Grande Tokyo Bay Hotel - 1-9 Maihama, Urayasu, Chiba 279-0031, Japan

PASS TYPE	STANDARD RATE
Emerging Companies & Start Ups, Academics, Charities, Veterinary Practices, Angel and VC Investors For Start-Ups with under £4m in Annual Revenue <small>Please note: Those offering consultancy or market intelligence services do not qualify for this rate</small>	\$650
Delegate Health, Nutrition and Tech Companies & VC Investors (under £100m in annual revenue)	\$1,899
Multinationals & Service Providers CROs, CMOs, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors and Companies over £100m in annual revenue	\$2,499

BIG SAVINGS WITH BIG BOOKINGS

SAVE 10% - Book a team of 3+

SAVE 15% - Book a team of 5+

**REGISTER
HERE**

Team discounts are only valid on industry rates and not in conjunction with any other offer or promotion. Payment Terms: Please note that all prices are plus VAT and a £49 processing fee will apply to any invoices requested. All Prices are in GBP. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please view our Cancellation Policy. QUESTIONS? Please email events@kisacoresearch.com.

